89 related articles for article (PubMed ID: 24254971)
21. Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells.
Delgado-Calle J; Arozamena J; Pérez-López J; Bolado-Carrancio A; Sañudo C; Agudo G; de la Vega R; Alonso MA; Rodríguez-Rey JC; Riancho JA
Mol Cell Endocrinol; 2013 Apr; 369(1-2):27-34. PubMed ID: 23415712
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
Ominsky MS; Li C; Li X; Tan HL; Lee E; Barrero M; Asuncion FJ; Dwyer D; Han CY; Vlasseros F; Samadfam R; Jolette J; Smith SY; Stolina M; Lacey DL; Simonet WS; Paszty C; Li G; Ke HZ
J Bone Miner Res; 2011 May; 26(5):1012-21. PubMed ID: 21542004
[TBL] [Abstract][Full Text] [Related]
23. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
24. Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers.
Sun X; Yang K; Wang C; Cao S; Merritt M; Hu Y; Xu X
Int J Med Sci; 2015; 12(3):270-9. PubMed ID: 25798053
[TBL] [Abstract][Full Text] [Related]
25. The effect of recombinant human bone morphogenetic protein-2 on the osteogenic potential of rat mesenchymal stem cells after several passages.
Ishikawa H; Kitoh H; Sugiura F; Ishiguro N
Acta Orthop; 2007 Apr; 78(2):285-92. PubMed ID: 17464620
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.
Roudier M; Li X; Niu QT; Pacheco E; Pretorius JK; Graham K; Yoon BR; Gong J; Warmington K; Ke HZ; Black RA; Hulme J; Babij P
Arthritis Rheum; 2013 Mar; 65(3):721-31. PubMed ID: 23233270
[TBL] [Abstract][Full Text] [Related]
27. The in vitro and in vivo treatment effects of overexpressed lentiviral vector-mediated human BMP2 gene in the femoral bone marrow stromal cells of osteoporotic rats.
Zhao B; Wang Q; Tao T; Li J; Lin Q
Int J Mol Med; 2013 Dec; 32(6):1355-65. PubMed ID: 24068163
[TBL] [Abstract][Full Text] [Related]
28. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
29. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor.
Cohen-Kfir E; Artsi H; Levin A; Abramowitz E; Bajayo A; Gurt I; Zhong L; D'Urso A; Toiber D; Mostoslavsky R; Dresner-Pollak R
Endocrinology; 2011 Dec; 152(12):4514-24. PubMed ID: 21952235
[TBL] [Abstract][Full Text] [Related]
30. Strongly enhanced levels of sclerostin during human fracture healing.
Sarahrudi K; Thomas A; Albrecht C; Aharinejad S
J Orthop Res; 2012 Oct; 30(10):1549-55. PubMed ID: 22508529
[TBL] [Abstract][Full Text] [Related]
31. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
32. Dependence of mesenchymal cell responses on duration of exposure to bone morphogenetic protein-2 in vitro.
Puleo DA
J Cell Physiol; 1997 Oct; 173(1):93-101. PubMed ID: 9326453
[TBL] [Abstract][Full Text] [Related]
33. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
34. Application of anti-Sclerostin therapy in non-osteoporosis disease models.
Jacobsen CM
Bone; 2017 Mar; 96():18-23. PubMed ID: 27780792
[TBL] [Abstract][Full Text] [Related]
35. The effect of bone morphogenetic protein-2 on rat intervertebral disc cells in vitro.
Tim Yoon S; Su Kim K; Li J; Soo Park J; Akamaru T; Elmer WA; Hutton WC
Spine (Phila Pa 1976); 2003 Aug; 28(16):1773-80. PubMed ID: 12923462
[TBL] [Abstract][Full Text] [Related]
36. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
Piters E; Culha C; Moester M; Van Bezooijen R; Adriaensen D; Mueller T; Weidauer S; Jennes K; de Freitas F; Löwik C; Timmermans JP; Van Hul W; Papapoulos S
Hum Mutat; 2010 Jul; 31(7):E1526-43. PubMed ID: 20583295
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing.
Agholme F; Macias B; Hamang M; Lucchesi J; Adrian MD; Kuhstoss S; Harvey A; Sato M; Aspenberg P
J Orthop Res; 2014 Mar; 32(3):471-6. PubMed ID: 24243768
[TBL] [Abstract][Full Text] [Related]
38. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
[TBL] [Abstract][Full Text] [Related]
39. Sclerostin: therapeutic horizons based upon its actions.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
[TBL] [Abstract][Full Text] [Related]
40. The effect of 3-hydroxybutyrate on the in vitro differentiation of murine osteoblast MC3T3-E1 and in vivo bone formation in ovariectomized rats.
Zhao Y; Zou B; Shi Z; Wu Q; Chen GQ
Biomaterials; 2007 Jul; 28(20):3063-73. PubMed ID: 17418401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
